other material
confidence high
sentiment positive
materiality 0.85
Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks
Monte Rosa Therapeutics, Inc.
- In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).
- NEK7 degradation ~80-90% in T cells across all dose levels (5-400 mg); favorable safety with mild/moderate AEs, no dose dependency.
- Median IL-6 dropped 55% to below cardiovascular risk threshold; CSF IL-6 decreased 75% in two subjects, suggesting CNS effect.
- Plan to initiate Phase 2 GFORCE-2 study in ASCVD in 2026; expand GFORCE-1 with readout H2 2026.
- Also evaluating Phase 2 studies in MASH, gout, recurrent pericarditis; collaborator Novartis to initiate Phase 2 studies of MRT-6160 in 2026.